Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach

Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach

Eltrombopag is a thrombopoietin receptor (MPL) agonist approved for the treatment of primary immune thrombocytopenia (ITP). Recent evidence shows that some patients may sustain platelet counts following eltrombopag discontinuation. The systemic immunomodulatory response that resolves ITP in some pat...

Full description

Bibliographic Details
Main Authors: Maria L. Lozano, Cristina Segú-Vergés, Mireia Coma, María T. Álvarez-Roman, José R. González-Porras, Laura Gutiérrez, David Valcárcel, Nora Butta
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:International Journal of Molecular Sciences
Subjects:
eltrombopag
primary immune thrombocytopenia
immunomodulation
in silico
systems biology
mathematical modelling
Online Access:https://www.mdpi.com/1422-0067/22/13/6907

Internet

https://www.mdpi.com/1422-0067/22/13/6907

Similar Items